Core Viewpoint - BriaCell Therapeutics Corp. has successfully closed a public offering of 12 million units, raising gross proceeds of $15 million to support its cancer immunotherapy development [1][3]. Group 1: Offering Details - The offering consisted of 12,000,000 units, each unit priced at $1.25, which includes one common share or one pre-funded warrant and one warrant [1]. - Each pre-funded warrant allows the purchase of one common share at an exercise price of $0.001, while each warrant is exercisable at $1.50 per share for five years [1]. - The offering was conducted without a Canadian prospectus, relying on an exemption under the TSX Company Manual [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital, general corporate purposes, and advancing business objectives [3]. Group 3: Regulatory Information - A registration statement on Form S-1 was filed with the SEC and became effective on July 15, 2025, with the offering made only by means of a prospectus [4].

Core Points - BriaCell Therapeutics Corp. announced a public offering of 12,000,000 units at a price of $1.25 per unit, aiming for gross proceeds of $15 million before expenses [1][3] - Each unit consists of one common share (or a Pre-Funded Warrant) and one Warrant, with the Warrant allowing the purchase of one common share at an exercise price of $1.50, expiring five years from issuance [1][3] - The offering is expected to close on July 16, 2025, subject to customary closing conditions [2] Financial Details - The net proceeds from the offering will be used for working capital, general corporate purposes, and advancing business objectives [3] - The offering is being facilitated by ThinkEquity as the sole placement agent [3] Regulatory Information - A registration statement on Form S-1 was filed with the SEC and became effective on July 15, 2025, with the offering being made only by means of a prospectus [4]

Company Overview - BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [4] Upcoming Events - The company will host two virtual investor presentations on June 12, 2025, and June 26, 2025, both at 12:00 PM EDT [1][2] - Stakeholders, investors, and individual followers are encouraged to register for these live events [1] Registration Information - Interested participants must register using provided links, with a note that live event access may be limited, but replays will be available on the company's investor website [2][3]

Group 1 - BriaCell Therapeutics Corp. has completed an underwritten public offering of 3,066,666 units, raising approximately $13.8 million in gross proceeds at a price of $4.50 per unit [1][2] - Each unit consists of one common share (or a pre-funded warrant) and one warrant, with the warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXZ" [1] - The warrants are immediately exercisable at an exercise price of $5.25 per share and expire five years from the date of issuance [1] Group 2 - The net proceeds from the offering will be used for working capital requirements, general corporate purposes, and to advance business objectives [2] - ThinkEquity acted as the sole book-running manager for the offering [2] Group 3 - A registration statement on Form S-1 was filed with the SEC and became effective on April 24, 2025, allowing the offering to proceed [3]

Core Points - BriaCell Therapeutics Corp. announced a public offering of 3,066,666 units at a price of $4.50 per unit, aiming for gross proceeds of approximately $13.8 million [1][2] - Each unit consists of one common share (or Pre-Funded Warrant) and one Warrant, with the Warrants approved for listing on the Nasdaq Capital Market under the symbol "BCTXZ" [1] - The offering is expected to close on April 28, 2025, subject to customary closing conditions [2] - The net proceeds will be used for working capital, general corporate purposes, and advancing business objectives [3] - A registration statement related to the securities was filed with the SEC and became effective on April 24, 2025 [4] Company Information - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care [6]